Opko Health SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 15, 2026, 4:07 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Financial statements and exhibits
AI summary, unreviewedOPKO Health agrees to sell BioReference lab assets to LabCorp for $722 million cash plus up to $150 million earnout
8-KOct. 2, 2026, 4:12 p.m. ETView on SEC.gov
Other events
AI summary, unreviewedOPKO Health Triggers Conversion Right on $121 Million 3.75% Convertible Notes, Elects Share Settlement
10-Q/AAug. 28, 2026, 4:24 p.m. ETView on SEC.gov
10-Q/AAug. 28, 2026, 4:20 p.m. ETView on SEC.gov
8-KAug. 14, 2026, 4:27 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Creation of a direct financial obligation · Financial statements and exhibits
4July 28, 2026, 4:24 p.m. ETView on SEC.gov
4July 28, 2026, 4:21 p.m. ETView on SEC.gov
10-QJuly 27, 2026, 4:12 p.m. ETView on SEC.gov
8-KJuly 27, 2026, 4:08 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits